Last reviewed · How we verify
NCT05808049
A Clinical Trial to Evaluate the Efficacy and Safety of MXP22 on Liver Health
NA trial testing MXP22 (Probiotic and antioxidant capsule) in Non-Alcoholic Fatty Liver Disease in 60 participants. Completed in 4 July 2023.
4 July 2023
Quick facts
| Lead sponsor | Vedic Lifesciences Pvt. Ltd. |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | other |
| Enrollment | 60 |
| Start date | 6 October 2022 |
| Primary completion | 4 July 2023 |
| Estimated completion | 4 July 2023 |
| Sites | 2 locations across India |
Drugs / interventions tested
- MXP22 (Probiotic and antioxidant capsule)
- Placebo (Microcrystalline Cellulose)
Conditions studied
- Non-Alcoholic Fatty Liver Disease — all drugs for Non-Alcoholic Fatty Liver Disease →
Sponsor
Vedic Lifesciences Pvt. Ltd. — full company profile →
Who can join
Adults 30 to 60, any sex, with Non-Alcoholic Fatty Liver Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A randomized, double blind, placebo controlled clinical trial to evaluate the efficacy and safety of MXP22 on liver health
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Non-alcoholic fatty liver disease: Immunological mechanisms and current treatments.
Petagine L, Zariwala MG, Patel VB. · · 2023 · cited 27× · PMID 37701135 · DOI 10.3748/wjg.v29.i32.4831
Verify or expand the search:
- PubMed search for NCT05808049
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Non-Alcoholic Fatty Liver Disease
Currently open trials in the same condition.
- NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting
- NCT07294963 — Impact of Lifestyle Interventions on Cognitive Decline in Non-alcoholic Fatty Liver Disease · NA · recruiting
- NCT07130318 — Mediterranean Diet in Familial Mediterranean Fever: Is Fatty Liver Affected by Addition of Aerobic Exercise · NA · recruiting
- NCT06355310 — Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease · Phase 2 · recruiting
- NCT06863376 — Evaluating the Safety and Efficacy of Carbocisteine in the Treatment of Nonalcoholic Fatty Liver Disease Patients · Phase 2 · recruiting
Other Vedic Lifesciences Pvt. Ltd. trials
Trials by the same sponsor.
- NCT07141368 — Single Oral Dose Comparative Bioavailability Study of Investigational Product in Healthy Human Subjects Under Fasting Co · NA · not yet recruiting
- NCT07033754 — A Study to Assess the Effect Probiotic Supplement on Immune Health in Teachers Prone to Upper Respiratory Tract Infectio · NA · not yet recruiting
- NCT06917287 — A Clinical Study to Evaluate the Efficacy of Native CT-II® in Individuals With Knee Osteoarthritis · NA · recruiting
- NCT06859346 — A Clinical Study to Assess the Effect of Tisina Complex on Cognitive Health in Individuals With Mild Cognitive Impairmen · NA · completed
- NCT06473246 — A Study to Determine Safety, Pharmakokinetics and Efficacy of the Different Doses of VL-SE-01 in Healthy Participants. · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05808049 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Vedic Lifesciences Pvt. Ltd.
- Last refreshed: 6 September 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05808049.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing